Mediclin AG reports steady growth in first nine months of 2025
Offenburg, 4 November 2025 – The German health‑care provider Mediclin AG (ticker MED, WKN 659 510) disclosed its consolidated operating results for the first nine months of 2025, showing a solid performance that aligns with market expectations.
Key financial highlights
| Metric | 9 Months 2025 | 9 Months 2024 | Change |
|---|---|---|---|
| Group sales | €586.9 million | €558.2 million | +€28.7 million (5.1 %) |
| Operating result | €48.9 million | €34.5 million | +€14.4 million |
| Capacity utilisation | 86.8 % | 86.0 % | +0.8 pp |
| Post‑acute segment sales | €394.6 million | €361.2 million | +€33.4 million (9.3 %) |
| Post‑acute segment operating result | €47.6 million | €38.0 million | +€9.6 million |
| Material cost ratio | 19.5 % | 20.4 % | –0.9 pp |
| Absolute material cost | €77.0 million | €73.8 million | +€3.2 million |
Segment performance
Mediclin’s post‑acute division – which includes outpatient and rehabilitation services – delivered a 9.3 % rise in sales, reaching €394.6 million. The segment’s operating result increased by €9.6 million to €47.6 million, underscoring efficient cost management. The material cost ratio fell by 0.9 percentage points, signalling tighter control over supplies and services.
Overall capacity utilisation remained stable at 86.8 %, slightly above the 86.0 % recorded in the same period last year, indicating that the company continues to operate near full capacity without overextending its resources.
Market context
With a market capitalization of €175.75 million and a price‑to‑earnings ratio of 5.36, Mediclin trades at a valuation that reflects its steady earnings profile. The share price closed at €3.66 on 2 November 2025, within a 52‑week range of €2.32 to €3.78.
Outlook
While the company did not publish forward guidance in this release, the combination of revenue growth, expanding operating margins and controlled material costs suggests a resilient business model. The stable utilisation rate indicates room to absorb additional demand without compromising service quality.
The 9‑month figures confirm that Mediclin AG remains on track to meet the expectations set by analysts, reinforcing investor confidence in its strategic focus on comprehensive health‑care provision across Germany.